Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
Dana-Farber Cancer Institute, Boston, Massachusetts David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York Sarah Cannon Research Institute, Nashville, Tennessee Belgium
UZ Leuven Europe Leuven, Leuven Netherlands
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam South Korea
Seoul National University Hospital, Seoul